Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.
In a groundbreaking development, researchers have harnessed the power of AI and machine learning to analyze patient data, enabling the prediction of Alzheimer's disease up to 7 years before symptoms manifest, with high cholesterol and osteoporosis emerging as key predictors.
Breakthrough AI tools developed by Cambridge researchers can accurately predict cystic fibrosis progression, enabling personalized treatment plans tailored to individual patients' disease trajectories, competing health risks, and past cases, representing a major step towards precision healthcare.
In a groundbreaking development, the FDA has approved a key component of Precision Neuroscience's brain implant system, paving the way for paralyzed patients to potentially regain speech and movement through a cutting-edge brain-computer interface technology that rivals efforts by Neuralink, Synchron, and other prominent players.
Researchers developed a multimodal AI tool that combines language models and graph-based models to efficiently design new molecules with desired properties from natural language queries, outperforming existing methods and potentially automating the entire molecule design and synthesis process.
Pioneering a privacy-first approach, researchers are developing secure AI agents that prioritize data minimization, encryption, and rigorous auditing to gain user trust, drive adoption in regulated sectors, and simplify compliance with privacy regulations like HIPAA, GDPR, and CCPA.
In a groundbreaking collaboration, Ai2 and Google Cloud have jointly invested $20 million to establish the Cancer AI Alliance, leveraging AI's potential to accelerate cancer research through shared models and secure data analytics powered by Google's cloud infrastructure.
Scientists developed a starfish-shaped wearable device that leverages AI to precisely track heart health in real time with over 90% accuracy, even during movement, enabling comfortable long-term at-home monitoring with wireless charging and skin-friendly materials.
Google-backed AI drug discovery startup Isomorphic Labs secured a staggering $600 million in funding led by Thrive Capital, fueling its AI engine's development and advancing partnerships with pharmaceutical giants like Eli Lilly and Novartis worth billions to revolutionize drug design.
Alphabet's AI drug discovery subsidiary Isomorphic Labs secures $600 million funding from Thrive Capital to accelerate development of its AI-powered drug design platform and advance its drug candidates into clinical trials, leveraging technology like DeepMind's AlphaFold.